First Reported Use of the Faxitron LOCalizer™ Radiofrequency Identification (RFID) System in Europe - A Feasibility Trial, Surgical Guide and Review for Non-palpable Breast Lesions.
Faxitron
LOCalizer™
Localizer
RFID
breast
lesion
marking
non-palpable
nonpalpable
radiofrequency identification device
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
10
04
2019
revised:
20
06
2019
accepted:
27
06
2019
entrez:
1
9
2019
pubmed:
1
9
2019
medline:
6
2
2020
Statut:
ppublish
Résumé
The problem of adequately marking any given lesion within a breast surgical site is commonly solved by introducing a titanium clip. However, clip dislocation and/or stereotactic hook-wire dislocation are common problems. An ideal solution would be a clip that can be easily found without the use of stereotactic intervention. This work reviews the available data on radiofrequency identification devices (RFID) in breast surgery, reports initial experience data in Europe and discusses surgical pitfalls, advantages and disadvantages. This study represents a single center, consecutively recruited, initiation trial with subsequent surgeon questionnaire for the first institution in Europe to report Faxitron LOCalizer™ chip data. Four patients with non-palpable tumors were marked with the system and were correlated via mammography, pre- and intra-operative ultrasound and pathology. Data were then compared to available literature and a literature review was added. The four patients marked with this RFID system, displayed a 100% success location rate at a 0% complication rate. Surgeons evaluated the new system as being safe to use and only slightly more difficult to place compared to a standard clip. A significant improvement in ultrasound localization and intraoperative localization was also reported for the LOCalizer™ system when compared to a standard titanium clip. This trial added a small number of consecutively recruited patients to an existing number of available data, resulting in a total of 121 evaluated and reviewed Faxitron LOCalizer™ marked non-palpable in-breast lesions worldwide.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The problem of adequately marking any given lesion within a breast surgical site is commonly solved by introducing a titanium clip. However, clip dislocation and/or stereotactic hook-wire dislocation are common problems. An ideal solution would be a clip that can be easily found without the use of stereotactic intervention. This work reviews the available data on radiofrequency identification devices (RFID) in breast surgery, reports initial experience data in Europe and discusses surgical pitfalls, advantages and disadvantages.
PATIENTS AND METHODS
METHODS
This study represents a single center, consecutively recruited, initiation trial with subsequent surgeon questionnaire for the first institution in Europe to report Faxitron LOCalizer™ chip data. Four patients with non-palpable tumors were marked with the system and were correlated via mammography, pre- and intra-operative ultrasound and pathology. Data were then compared to available literature and a literature review was added.
RESULTS
RESULTS
The four patients marked with this RFID system, displayed a 100% success location rate at a 0% complication rate. Surgeons evaluated the new system as being safe to use and only slightly more difficult to place compared to a standard clip. A significant improvement in ultrasound localization and intraoperative localization was also reported for the LOCalizer™ system when compared to a standard titanium clip.
CONCLUSION
CONCLUSIONS
This trial added a small number of consecutively recruited patients to an existing number of available data, resulting in a total of 121 evaluated and reviewed Faxitron LOCalizer™ marked non-palpable in-breast lesions worldwide.
Identifiants
pubmed: 31471405
pii: 33/5/1559
doi: 10.21873/invivo.11637
pmc: PMC6754990
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1559-1564Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Clin Breast Cancer. 2018 Aug;18(4):e555-e559
pubmed: 29429940
AJR Am J Roentgenol. 2015 Jun;204(6):W720-3
pubmed: 26001262
Magn Reson Imaging Clin N Am. 2018 May;26(2):235-246
pubmed: 29622128
Breast Cancer Res Treat. 2019 May;175(1):165-170
pubmed: 30689105
Wien Klin Wochenschr. 2014 Feb;126(3-4):90-4
pubmed: 24442857
World J Surg Oncol. 2018 Sep 11;16(1):184
pubmed: 30205823
Anticancer Res. 2016 May;36(5):2423-7
pubmed: 27127152
J Am Coll Surg. 2012 Oct;215(4):524-33
pubmed: 22770865
Eur J Surg Oncol. 2019 Apr;45(4):578-583
pubmed: 30737056
Ann Med Surg (Lond). 2016 Feb 24;7:7-8
pubmed: 27158488
AJR Am J Roentgenol. 2008 Nov;191(5):1359-65
pubmed: 18941069
Int J Surg. 2014;12(6):572-7
pubmed: 24735893
Acad Radiol. 2019 Jun;26(6):805-819
pubmed: 30143401